0HF3.LSE Cencora
- Market cap
- -
- P/E
- 40.9x
- P/B
- -
- ROE
- 129.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is 0HF3.LSE undervalued?
Graham numberThe Graham number of Cencora cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cencora fundamental analysis
No fundamental analysis for Cencora yet.
Cencora stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cencora
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and o…
Full company profileCencora financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cencora annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 147B | 153B | 168B | 180B | 190B | 214B | 239B | 262B | 294B | 321B | 332B |
| Gross Profit | 3.77B | 4.15B | 4.11B | 4.53B | 4.79B | 6.27B | 7.60B | 8.81B | 8.82B | 10.5B | 12.6B |
| Operating Income | 1.68B | 2.02B | 1.65B | 1.87B | 2.02B | 2.68B | 2.75B | 2.34B | 3.16B | 2.81B | 4.75B |
| EBITDA | 2.07B | 2.44B | 1.87B | 2.50B | 2.44B | 3.18B | 3.49B | 3.51B | 3.36B | 3.70B | 5.49B |
| Net Income | 1.43B | 364M | 1.66B | 855M | -3.41B | 1.54B | 1.70B | 1.75B | 1.51B | 1.55B | 3.95B |
| EPS | 6.32 | 1.64 | 7.53 | 4.04 | -17 | 7.39 | 8.04 | 8.53 | 7.53 | 8.02 | 20 |
| Balance Sheet | |||||||||||
| Total Assets | 33.6B | 35.3B | 38.0B | 39.5B | 44.3B | 57.3B | 56.6B | 62.6B | 67.1B | 76.6B | 83.8B |
| Total Liabilities | 31.5B | 33.3B | 35.0B | 36.5B | 45.1B | 56.8B | 56.5B | 61.9B | 66.3B | 74.8B | 80.6B |
| Shareholders' Equity | 2.13B | 2.06B | 2.93B | 2.88B | -1.02B | 223M | -212M | 522M | 646M | 1.51B | 3.05B |
| Cash & Short-term Investments | 2.77B | 2.44B | 2.49B | 3.37B | 4.60B | 2.55B | 3.53B | 2.59B | 3.13B | 4.36B | 2.86B |
| Total Debt | 4.46B | 3.79B | 4.66B | 4.49B | 4.60B | 7.81B | 6.73B | 5.89B | 4.39B | 10.7B | 11.7B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.18B | 1.50B | 1.41B | 2.34B | 2.21B | 2.67B | 2.70B | 3.91B | 3.48B | 3.88B | 2.25B |
| Capital Expenditure | 465M | 466M | 336M | 310M | 370M | 438M | 496M | 458M | 487M | 668M | 681M |
| Free Cash Flow | 2.71B | 1.04B | 1.07B | 2.03B | 1.84B | 2.23B | 2.21B | 3.45B | 3.00B | 3.21B | 1.57B |
| Ratios | |||||||||||
| ROE | 67.1% | 17.7% | 56.5% | 29.7% | - | 689.5% | - | 334.3% | 233.6% | 103.1% | 129.6% |
| ROA | 4.2% | 1.0% | 4.4% | 2.2% | -7.7% | 2.7% | 3.0% | 2.8% | 2.2% | 2.0% | 4.7% |
| Net Profit Margin | 1.0% | 0.2% | 1.0% | 0.5% | -1.8% | 0.7% | 0.7% | 0.7% | 0.5% | 0.5% | 1.2% |
| Debt to Equity | 2.10x | 1.84x | 1.59x | 1.56x | - | 34.95x | - | 11.29x | 6.79x | 7.13x | 3.84x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cencora dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- 28.1%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | 437M | 2.25 | 28.1% |
| 2024 | USD 416M | 2.08 | 27.6% |
| 2023 | USD 399M | 1.95 | 22.8% |
| 2022 | USD 392M | 1.85 | 23.1% |
| 2021 | USD 367M | 1.76 | 23.8% |
| 2020 | USD 344M | 1.68 | - |
| 2019 | USD 339M | 1.60 | 39.6% |
| 2018 | USD 333M | 1.51 | 20.1% |
| 2017 | USD 320M | 1.45 | 87.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Cencora
- Insiders 4.30%
- Institutions 95.70%
- Public & others 0.00%
- Free float 180M
Cencora company profile
- Company name
- Cencora
- Ticker
- 0HF3.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 47,000
- Fiscal year end
- September
- Address
- 1 West First Avenue, Conshohocken, PA, United States, 19428-1800
- Phone
- 610 727 7000
- Website
- cencora.com
About Cencora
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Cencora management
10- Dr. Robert P. Mauch Ph.D., PharmDPresident, CEO & Director · born 1967
- Ms. Elizabeth S. Campbell J.D.Executive VP & Chief Legal Officer · born 1975
- Mr. James F. Cleary Jr.Advisor · born 1963
- Ms. Silvana BattagliaAdvisor · born 1968
- Ms. Eva C. BorattoExecutive VP & CFO · born 1967
- Mr. Lazarus KrikorianSenior VP, Chief Accounting Officer & Corporate Controller · born 1965
- Mr. Pawan Singh VermaExecutive VP and Chief Data & Information Officer · born 1977
- Mr. Bennett S. MurphySenior VP Of Investor Relations & Enterprise Productivity and Treasury
- Ms. Samantha L. HammockExecutive VP & Chief Human Resources Officer · born 1979
- Mr. Richard TremonteEVP and President of U.S. Pharmaceuticals & Animal Health